Brief: Marker Therapeutics Receives USAN Approval For "Zelenoleucel" As Nonproprietary Name For MT-401
23/06/2020 12:16
June 23 (Reuters) - Marker Therapeutics Inc MRKR.O :
* MARKER THERAPEUTICS RECEIVES USAN APPROVAL FOR
"ZELENOLEUCEL" AS
NONPROPRIETARY NAME FOR MT-401, MULTI-TUMOR-ASSOCIATED ANTIGEN
TARGETED T CELL PRODUCT FOR ACUTE MYELOID LEUKEMIA
Source text for Eikon: ID:nPn2TcMTHa
Further company coverage: MRKR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79